BRCA1 and triple-negative breast carcinoma: Furthermore, in light of the recently published data on the OlympiA trial [30] and the above-mentioned rate of 40.7% (n = 72) of PVs among counselees with triple-negative breast cancer as well as the predominance of the genes BRCA1/2 among these PVs, the clinical relevance of genetic analysis as an essential part of therapy planning is underlined by these data.